期刊文献+

氚标记吲哚美辛在荷瘤鼠血液及瘤体内的药代动力学研究

Study on Pharmacokinetics of ^3H-IN in Tumor-bearing Mice's Blood and Tumor
下载PDF
导出
摘要 研究氚标记吲哚美辛(3H-IN)在荷瘤小鼠血液及瘤体内的分布及药代动力学特征,进一步探讨其在肿瘤中的蓄积现象。荷Lewis肺癌小鼠灌胃给药后于不同时间点取血和瘤组织,分别测定其放射性计数及药物浓度。结果表明,3H-IN蓄积于肿瘤组织中,并以较高水平维持较长时间,在此期间,瘤体中吲哚美辛药物原形则迅速消除,且浓度远低于血药浓度。小鼠血浆和瘤体内不同时相IN的药物浓度数据用DASver1.0实用药代动力学程序处理,选择二室模型,且权重系数为1/cc拟合药-时曲线,得出主要药代动力学参数。结果提示,3H-IN有很好的瘤组织趋向性,其药物原形并非在肿瘤中蓄积的主要成分。 Pharmacokinetics of ^3H-IN in tumor-bearing Mice's blood and tumor are studied, and the accumulated phenomenon of IN in tumor are further discussed. Blood and tumor of mice are taken at different time after being taken ^3 H-IN orally, radioactivities are counted and concentrations of IN are measured in the tissues. The results show that ^3 H-IN accumulate in tumor tissue with high levels for a long time, but at the same time IN prototype is cleared rapidly and it's concentrations are far lower than in blood. Pharmacokinetic parameters are calculated by DAS verl. 0 software. The results demonstrate that ^3 H-IN has good affinity to the tumor tissue and the major part accumulated in tumor is not the IN prototype.
出处 《同位素》 CAS 北大核心 2007年第1期41-44,共4页 Journal of Isotopes
基金 辽宁省教育厅(A类攻关计划)资助项目(编号:2004D160)
关键词 氚标记 吲哚美辛 LEWIS肺癌 药代动力学 ^3 H-labeled indomethacin lewis lung cancer pharmacokinetics
  • 相关文献

参考文献9

  • 1周丽坤,张彩霞.氚标记吲哚美辛的亲肿瘤实验研究[J].中华核医学杂志,2004,24(4):209-209. 被引量:9
  • 2张彩霞,徐微娜,周丽坤,王爽.氚示踪法研究吲哚美辛在C57小鼠体内的分布及其抗肿瘤作用[J].同位素,2004,17(4):214-217. 被引量:1
  • 3REMMEL RP,CREWS BC,KOZAK KR,et al.Studies on the Metabolism of the Novel,Selective Cyclooxygenase-2 Inhibit or Indomethacin Phenethylamide in Mouse,Mouse,and Human Liver Microsomes:Identification of Active Metabolites[J].Drug Metabolism and Disposition,2004,32:113-122.
  • 4曹德善,刘利萍,王广基.吲哚美辛缓释片的研制及其生物利用度的研究[J].中国药科大学学报,2002,33(5):383-387. 被引量:9
  • 5YAMADA I,NAGAMATSU Y,IMAYOSHI T,et al.Pharmacokinetic Behaviour in Polymorphonuclear Lieucocytes of N,N-dimethylcarbamoylmethylalpha,2-dimethyl-5H-[1]benzopyran o[2,3-b]-pyridine-7-acetate (Y-23023),a New Prodrug Type of Anti-inflammatory Agent,and Indomethacin After Oral Administrations in Rats[J].Pharmacol,1994,46(7):614-616.
  • 6LIU S,KAMIJO M,TAKAYASU T,et al.Direct Analysis of Indomethacin in Rat Plasma Using a Column-switching High-performance Liquid Chromatographic System[J].J Chroma Togr B Analyt Technol Biomed Life Sci,2002,767 (1):53-60.
  • 7LI YC,GUAN CT.Pharmacokinetics of Lactosaminated Recomb Inant Human Growth Hormone in Mice[J].Acta Pharmacol Sin,2001,22(5):450.
  • 8王春华,冯亦璞,吴元鎏.丁基苯酞在大鼠中代谢产物的研究[J].药学学报,1997,32(9):641-646. 被引量:8
  • 9VREE TB,Vanden BIGGELAAR-MARTEA M,VERWEY-BAN WISSEN CP.Determination of Indomethacin,Its Metabolites and Their Glucuronides in Human Plasma and Urine by Means of Direct Gradient HPLC Analysis:Preli Minary Pharmacokinetics and Effect of Probenecid[J].J Chromatogr,1993,616(2):271-282.

二级参考文献23

  • 1张玉琥,张彤梅,黄铖,李汉蕴.吲哚美辛控释胶囊的制备及人体生物利用度[J].中国药学杂志,1994,29(9):533-536. 被引量:16
  • 2张彤梅,张玉琥,李汉蕴.吲哚美辛控释胶囊稳态血药浓度测定及稳定性考察[J].中国药学杂志,1994,29(11):673-676. 被引量:3
  • 3国家经贸委科技司 国家医药管理局.国家级药物制剂新产品开发指南[M].北京,1993..
  • 4张彩霞 徐薇娜 张耀祥 等.消炎痛与153Sm-EDTMP对骨转移瘤的止痛效果观察[J].中华校医学杂志,2001,21:117-117.
  • 5Stoll BA. Indomethacin in breast cancer. Lancent, 1973, 2: 384.
  • 6Panje WR. Regression of head and neck carcinoma with a prostaglandin synthesis inhibitor. Arch Otolaryngol, 1981, 107: 658-663.
  • 7Cross DS, Platt JL, Juhn SK, et al. Administration of a prostaglandin synthesis inhibitor associated with an increased immune cell infiltrate in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg, 1992, 118: 526-528.
  • 8Kim CD, Sung MW, Lee SJ, et al. The effect of prostaglandin and its inhibitor on antibody-dependent cellular cytoxicity against human squamous cell carcinoma of haed and neck. Anticancer Res, 1999, 19 (1A): 455-459.
  • 9Lin Z, Jian Y, Ben HP, et al. Role of BAX in the apoptotic response to anticancer agents. Science, 2000, 290: 989-992.
  • 10胡盾,药学学报,1996年,31卷,13页

共引文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部